EU Joint Clinical Assessment (JCA) is still early in its implementation. Much of the formal framework is already described in guidance and legislation. What is beginning to change is how those requirements are playing out in practice for development teams.
Not as outcomes or decisions, but as patterns of friction, uncertainty and exposure that are appearing earlier than many teams expected.
For rare disease and advanced therapy programmes that remain some distance from formal JCA timelines, these early signals matter because they shape which decisions become difficult to revisit later.
Planning is becoming more forward-looking
Recent work by the HTA Coordination Group on emerging health technologies shows that planning activity for 2026 is already supported by structured horizon scanning. This includes oncology products, advanced therapies and medical devices that may be eligible for joint assessment in future cycles.
The precise composition of that pipeline will change. The more relevant point for development teams is that EU HTA is no longer something that only becomes visible at the point of submission.
For teams working on assets that still feel “a few years out”, this shifts the practical question. It becomes less about when to start formal JCA preparation, and more about which assumptions are being set now that may be hard to adjust later.
Operational coordination is emerging as a pressure point
Early experience suggests that some of the challenges teams encounter are not scientific, but operational.
Timing dependencies between regulatory milestones, letters of intent and internal coordination across functions can create knock-on effects for scoping and planning. In a tightly sequenced process, small delays can reduce the time available to clarify evidence positioning or resolve uncertainty.
This is not about assigning blame or adding process. It reflects the reality that EU JCA brings regulatory and evidence planning closer together in time.
Larger organisations may have more capacity to absorb this. Leaner teams often have less margin for error, which makes early clarity particularly valuable.
Registry data require clearer positioning to be useful
Patient registries are widely recognised as an important source of information in rare diseases. In practice, however, how registry data are used and interpreted can vary across assessments.
For development teams, the key issue is not whether registries are valuable, but whether their purpose is clearly defined in assessment terms.
Registries are most useful when it is clear which uncertainty they are intended to address, such as natural history, disease severity, care pathways or outcome relevance. Without that clarity, teams can invest significant effort in data generation without confidence that the information will be interpreted consistently across different contexts.
What readiness starts to mean in practice
Taken together, these signals point to a subtle shift for development teams.
Readiness is not about predicting future assessment questions or building full dossiers early. It is about making a small number of upstream decisions more explicit, while there is still room to adjust them without disruption.
For lean rare disease and advanced therapy teams, that often means pressure-testing a few practical areas:
- Timeline ownership
Who is responsible for letters of intent, updates and coordination signals, and how robust is that in practice? - Evidence positioning
Which outcomes or comparators are implicitly central to the programme narrative, and where might interpretation vary across countries? - Registry intent
What specific uncertainty is the registry designed to reduce, and how would that be explained in assessment terms?
None of this requires formal JCA work today. But it can reduce avoidable exposure later.
A final note
If you are supporting a rare disease or advanced therapy programme and want to sense-check where readiness is already becoming visible — and where a small amount of early clarification could reduce future risk — I am always happy to compare notes.
Not to predict outcomes. Just to talk things through while there is still room to move.
This article was originally published in the Rare Focus newsletter and has been adapted for swii.ch.